Related Experiment Videos
Is xamoterol safe in chronic airflow obstruction?
J A Roberts1, V F Challenor, D G Waller
1Clinical Pharmacology, Southampton General Hospital, UK.
European Journal of Clinical Pharmacology
|January 1, 1992
Summary
Xamoterol did not change lung function or respiratory symptoms in patients with chronic airway obstruction (CAO). This suggests xamoterol may be a safe option for treating mild heart failure in this patient group.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Chronic airway obstruction (CAO) is a condition affecting lung function.
- Heart failure often coexists with CAO, complicating treatment.
- Xamoterol is a beta-1 selective adrenoceptor agonist.
Purpose of the Study:
- To evaluate the effect of xamoterol on lung function and respiratory symptoms in patients with CAO.
- To determine the safety and efficacy of xamoterol for mild heart failure in CAO patients.
Main Methods:
- A study involving 10 patients diagnosed with CAO.
- Treatment administered: xamoterol 200 mg twice daily for 7 days.
- Outcome measures included lung function tests and assessment of respiratory symptoms.
Main Results:
- Xamoterol treatment (200 mg b.i.d. for 7 days) showed no significant alteration in lung function.
- Respiratory symptoms remained unchanged in patients receiving xamoterol.
- No adverse effects on pulmonary parameters were observed.
Conclusions:
- Xamoterol does not negatively impact lung function or respiratory symptoms in CAO patients.
- These findings support the potential use of xamoterol for managing mild heart failure in individuals with CAO.
- Xamoterol may offer a therapeutic option for comorbid heart failure and CAO.